Spyre Therapeutics (SYRE) Change in Account Payables (2015 - 2026)
Spyre Therapeutics (SYRE) posted Change in Account Payables of $36000.0 for Q1 2026, down 99.26% on a QoQ basis from $4.9 million in Q4 2025, and down 98.81% year-over-year from $3.0 million in Q1 2025.
Spyre Therapeutics (SYRE) Change in Account Payables (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Change in Account Payables history runs 12 years deep, the most recent figure standing at $36000.0 for Q1 2026.
- Quarterly Change in Account Payables fell 98.81% year-over-year to $36000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (up 181.4% YoY) and the FY2025 annual result came in at $8.2 million, up 151.55% from the prior year.
- Change in Account Payables was $36000.0 for Q1 2026 at Spyre Therapeutics, down from $4.9 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $8.8 million in Q2 2024 and bottomed at -$17.5 million in Q3 2024.
- A 5-year average of -$631812.5 and a median of $29500.0 in 2025 frame the typical range for Change in Account Payables.
- Peak annual rise in Change in Account Payables reached 1237.67% in 2024, while the deepest fall reached 570.16% in 2024.
- Spyre Therapeutics' Change in Account Payables stood at $1.4 million in 2022, then tumbled by 121.23% to -$287000.0 in 2023, then sank by 193.73% to -$843000.0 in 2024, then surged by 677.82% to $4.9 million in 2025, then sank by 99.26% to $36000.0 in 2026.
- Business Quant data shows SYRE's Change in Account Payables at $36000.0 in Q1 2026, $4.9 million in Q4 2025, and $321000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn | - |
| 10 | Spyre Therapeutics | 256.61 Mn | 256.61 Mn | - | 36,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36,000.00 |
| Mar 31, 2026 | 36,000.00 |
| Dec 31, 2025 | 4.87 Mn |
| Dec 31, 2025 | 4.87 Mn |
| Sep 30, 2025 | 321,000.00 |
| Sep 30, 2025 | 321,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Mar 31, 2025 | 3.02 Mn |
| Mar 31, 2025 | 3.02 Mn |
| Dec 31, 2024 | -843,000.00 |
| Dec 31, 2024 | -843,000.00 |
| Sep 30, 2024 | -17.47 Mn |
| Sep 30, 2024 | -17.47 Mn |
| Jun 30, 2024 | 8.84 Mn |
| Jun 30, 2024 | 8.84 Mn |
| Mar 31, 2024 | -6.51 Mn |
| Mar 31, 2024 | -6.51 Mn |
| Dec 31, 2023 | -287,000.00 |
| Dec 31, 2023 | -287,000.00 |